About Us

Stimunity is an early-stage research company focused on the development of novel systemic and local formulations of STING agonists for cancer treatment. The Company is currently conducting a preclinical study to demonstrate proof of concept.

Portage shareholders own approximately 37% of Stimunity. Portage also serves as the Chairman of the Board and plays a strategic advisory role.

Pipeline

COMPANY
ASSET
INDICATION
STAGE

Logo Stimunity

ASSET
STING
STING
INDICATION
Solid Tumor
Solid Tumor
STAGE
IND-Enabling
Preclinical

Program

The Company’s technology, licensed from the University of Oxford, Institut Curie and Inserm, encapsulates endogenous STING-activating molecules in a virus-like particle (VLP) in order to activate the innate immune system and enhance T cell response against tumors. The technology is currently in preclinical studies to demonstrate proof of concept. The company has evaluated several formulations and is progressing both intratumoral and systemically administered programs.

Leadership

CEO and Founder

Sylvain brings 6 years of Business Development & Licensing Manager …

Scientific Advisor and Founder

Dr. Nicolas Manel is Director of Research at INSERM and Group …

Chairman of the Board

Dr. Walters has over 20 years of leadership and expertise in …

Business Advisor

Damien Salauze brings extensive drug-development experience from his time at …

Scientific Advisor

Dr. Jan Rehwinkel is a team leader at the University of Oxford. His …

Scientific Advisor

Dr. Sebastian Amigorena is Director of Research INSERM, and head of the …